A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
A phase 3 trial of Cemiplimab, Docetaxel, Vinorelbine and Gemcitabine in non-small-cell lung cancer, run by Maia Biotechnology, now recruiting.
Overview
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC is a phase 3 interventional study registered as NCT06908304 by Maia Biotechnology, with 300 participants planned, started 2025-12-08 and due to reach its primary completion in 2027-07-31. Interventions recorded: 6-Thio-2'-Deoxyguanosine, Cemiplimab, Docetaxel, Vinorelbine and Gemcitabine alone.
Similar pages
not linked directly; found by shared links- TrialTHIO Sequenced With Cemiplimab in Advanced NSCLC
Shares Maia Biotechnology, Cemiplimab, Non-small-cell lung cancer and the tag pipeline.
- TrialA Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
Shares Vinorelbine, Docetaxel, Gemcitabine and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC
Shares Docetaxel, Gemcitabine and the tag pipeline.
- TrialA Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Shares Docetaxel, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)
Shares Vinorelbine, Gemcitabine and the tag pipeline.
- TrialStudy of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Shares Vinorelbine, Gemcitabine and the tag pipeline.
- TrialAsian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
Shares Vinorelbine, Gemcitabine and the tag pipeline.
- TrialASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Shares Vinorelbine, Gemcitabine and the tag pipeline.